NCT04456803已完成3 期
A Study to Evaluate the Efficacy and Safety of Ferric Citrate Tablet for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 239
- 试验地点
- 20
- 主要终点
- The change in serum phosphorus levels
研究概览
简要总结
To evaluate the efficacy and safety of ferric citrate tablet in the control of serum phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.
详细描述
This is a multicenter, randomized, open-label, parallel, phase III study. This study is consisting of a Screening/Washout period (14 days) and a Treatment/Observation period (12 weeks). The subjects with regular hemodialysis should stop using the phosphorus binder before the Washout period. During the Treatment period, the subjects will be randomly assigned to the ferric citrate tablets group (study group) or sevelamer carbonate tablet group (control group) in the ratio of 1:1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Between the age of 18 and 75 years (including the boundary value) and no gender limitation;
- •Patients who maintain the hemodialysis schedule (including hemofiltration (HF) hemodialysis (HDF) hemoperfusion (HP)) as not less than 3 times a week in the 3 months before random enrollment.
- •Patients with a serum phosphorus level between 1.97 to 3.23 mmol/L (excluding the boundary value) after washout.
- •Kt/Vurea ≥1.2 or URR ≥65%.
- •Before the screening period, CKD-MBD related drug treatment is stable for more than one month, including the use of vitamin D (active vitamin D, vitamin D analogues, etc.) or calcimimetics (cinacalcet, etc.) and the dose remains unchanged.
- •The expected survival is greater than 6 months.
- •Willing to give written informed consent.
排除标准
- •Patients with a serum ferritin level ≥800 ng/mL or TSAT ≥50%.
- •Patients with hemochromatosis or patients receiving treatment for iron overload, or patients with paroxysmal sleep hemoglobinuria.
- •Patients who received blood transfusions within 3 months prior to Screening, or patients with hemoglobin ≤60 g/L.
- •Patients with intact-PTH >1000 pg/mL
- •Patients complicated with any of the following gastrointestinal diseases: acute peptic ulcer, chronic ulcerative colitis, localized enteritis, intestinal obstruction, habitual constipation (number of stools once per week), and chronic diarrhea (number of stools four times per day), or patients with a history of gastrectomy or enterectomy or patients who had undergone gastrointestinal surgery within 3 months prior to Screening, or patients with dysphagia.
- •Patients with impaired liver function (hepatic dysfunction or serum total bilirubin, aspartate aminotransferase or alanine aminotransferase ≥ 2 times the upper limit of normal) or patients with cirrhosis.
- •Patients with a history of parathyroidectomy (PTx) or percutaneous anhydrous ethanol injection (PEIT) within 6 months.
- •Patients with uncontrolled diabetes or uncontrolled high blood pressure or current active infectious diseases such as active viral hepatitis.
- •Patients with a history of severe allergies may be allergic to research drugs.
- •Patients with cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.) or cardiovascular disease (congestive heart failure of Class III or severer in NYHA classification) requiring hospitalization within 6 months prior to Screening, or patients who use antiarrhythmic drugs to control arrhythmias or who use antiepileptic drugs to control seizures.
- •Patients who plan to receive a kidney transplant during the study period.
- •Patients with a history of drug and alcohol abuse
- •Patients with active or advanced malignancy.
- •Women who are pregnant or lactating
- •Patients complicated with active bleeding or requiring anticoagulation therapy with citrate in hemodialysis
- •Patients who had participated in other clinical studies within 1 month prior to Screening.
- •Patients who are not suitable for participating in the trial according to the investigator's judgment
研究组 & 干预措施
Ferric citrate tablet
Experimental
Ferric citrate arm will receive ferric citrate tablets three times a day with each meal.
干预措施: Ferric citrate tablet (Drug)
Sevelamer carbonate tablet
Active Comparator
Sevelamer carbonate arm will receive sevelamer carbonate tablets three times a day with each meal.
干预措施: Sevelamer carbonate tablet (Drug)
结局指标
主要结局
The change in serum phosphorus levels
时间窗: 12 Weeks
The change in serum phosphorus levels at the end of treatment as compared to baseline (before the first dose).
次要结局
- The change in the level of intact-PTH levels.(week 4, 8 and 12)
- The proportion of subjects whose serum phosphorus levels reached the target(week 4, 6, 8 and 12)
- Changes in serum phosphorus levels(week 2, 4, 6, 8)
- Area under the curve of serum phosphorus level(week 0, 2, 4, 6, 8, 12)
- The change in serum calcium (corrected) levels.(week 4, 8 and 12)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
3 期
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing HemodialysisEnd Stage Renal DiseaseHyperphosphatemiaESRDNCT03984760Panion & BF Biotech Inc.240
已完成
4 期
Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency AnemiaIron-deficiencyAnemiaHypophosphatemiaNCT05098249Donat R. Spahn92
已完成
2 期
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of SerumEndstage Renal DiseaseNCT03010072Prim. Priv. Doz. Dr. Daniel Cejka40
已完成
3 期
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)Renal Failure Chronic Requiring HemodialysisNCT01322347Rockwell Medical Technologies, Inc.294
已完成
3 期
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis PatientsRenal Failure Chronic Requiring HemodialysisNCT01320202Rockwell Medical Technologies, Inc.305